$12m boost for peanut allergy treatment
Breakthrough Victoria has invested $12 million to progress Phase 2 clinical trials of a promising peanut allergy treatment, initially developed by Alfred Health and Monash University researchers.
Visitor information – Everything you need to know about visiting our sites.
Alfred Respiratory Medicine research seeks to advance knowledge, clinical care and patient outcomes in respiratory disease. Our research expertise spans laboratory-based research, clinical research, clinical trials, epidemiology and registry-based studies, qualitative research and implementation of research into practice.
Alfred Health is home to one of Australia’s largest departments of respiratory medicine. Respiratory medicine provides a unique environment for our research in diverse patient groups including:
We have a particular focus on advanced lung disease, with active research programs in adult and paediatric lung transplantation.
Our Respiratory Medicine research program is enhanced by state of the art respiratory and sleep physiology services. We offer clinical trials testing new respiratory treatments across the research pipeline, from first-in-disease to large Phase III and IV studies.
Respiratory Medicine research is multidisciplinary, linking senior clinician scientists, bench scientists, allied health professionals, primary care physicians and the community.
Our clinical and academic base is located at The Alfred, with experimental and clinical research laboratories located within the hospital and in the laboratories of Monash University at the Alfred Research Alliance.
In addition to our strong partnership with Monash University, we have research collaborations with a range of national and international partners including universities, research institutes, hospitals, industry, and leaders in patient advocacy.
McNeil JJ, Gibbs P, Orchard SG, Lockery JE, Bernstein WB, Cao Y, Ford L, Haydon A, Kirpach B, Macrae F, McLean C, Millar J, Murray AM, Nelson MR, Polekhina G, Reid CM, Richmond E, Rodríguez LM, Shah RC, Tie J, Umar A, Londen GJV, Ronaldson K, Wolfe R, Woods RL, Zalcberg J, Chan AT; ASPREE Investigator Group
(2021), JNCI-J NATL CANCER I, 113(3), 258-65
DOI: 10.1093/jnci/djaa114
Blakey J, Chung LP, McDonald VM, Ruane L, Gornall J, Barton C, Bosnic-Anticevich S, Harrington J, Hew M, Holland AE, Hopkins T, Jayaram L, Reddel H, Upham JW, Gibson PG, Bardin P
(2021), Respirology, 26(12), 1112-30
DOI: 10.1111/resp.14147
Button BM, Wilson LM, Burge AT, Kimmel L, Finlayson F, Williams E, Talbot A, Tierney A, King S, Holland AE, Keating D, Kotsimbos T, Wilson JW
(2021), ERJ Open Research, 7(3), 00120-2021
Breakthrough Victoria has invested $12 million to progress Phase 2 clinical trials of a promising peanut allergy treatment, initially developed by Alfred Health and Monash University researchers.
If you have been out and about in Melbourne recently it is likely you will have heard someone talking about their hayfever symptoms.
Are you getting enough sleep?
Sleep Health Week, running from September 25 to October 1, is a reminder for tired Aussies to take the time to take a closer look at their sleep health – with a theme of “Better Sleep, Better Health”.